Phio Pharmaceuticals Corp
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
PHIO$0.84+4.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| ITEM 6. | EXHIBITS |
|---|
EXHIBIT INDEX
| Incorporated by Reference Herein | |||
| Exhibit Number | Description | Form | Date |
| 3.1 | Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp. | Current Report on Form 8-K (File No. 001-36304) | November 19, 2018 |
| 3.2 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp. | Current Report on Form 8-K (File No. 001-36304) | January 14, 2020 |
| 3.3 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp. | Current Report on Form 8-K (File No. 001-36304) | January 25, 2023 |
| 3.4 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals Corp. | Current Report on Form 8-K (File No. 001-36304) | July 2, 2024 |
| 3.5 | Amended and Restated Bylaws of Phio Pharmaceuticals Corp. | Current Report on Form 8-K (File No. 001-36304) | May 2, 2022 |
| 4.1 | Form of Series C/D Warrant, dated July 12, 2024. | Current Report on Form 8-K (File No. 001-36304) | July 12, 2024 |
| 4.2 | Form of Placement Agent Warrant, dated July 12, 2024. | Current Report on Form 8-K (File No. 001-36304) | July 12, 2024 |
| 10.1 | Form of Inducement Letter Agreement, dated July 12, 2024, by and between Phio Pharmaceuticals Corp. and the Holders. | Current Report on Form 8-K (File No. 001-36304) | July 12, 2024 |
| 10.2 | Offer Letter, executed July 16, 2024, by and between the Company and Robert M. Infarinato. | Current Report on Form 8-K (File No. 001-36304) | August 1, 2024 |
| 31.1 | Sarbanes-Oxley Act Section 302 Certification of Principal Executive Officer. * | ||
| 31.2 | Sarbanes-Oxley Act Section 302 Certification of Principal Financial Officer. * | ||
| 32.1 | Sarbanes-Oxley Act Section 906 Certification of Principal Executive Officer. ** | ||
| 32.2 | Sarbanes-Oxley Act Section 906 Certification of Principal Financial Officer. ** | ||
| 101.INS | Inline XBRL Instance Document.* | ||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document.* | ||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document.* | ||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document.* | ||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document.* | ||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document.* | ||
| 104 | The cover page for this report, formatted in Inline XBRL (included in Exhibit 101).* | ||
| _________________ | |
|---|---|
| * | Filed herewith. |
| ** | Furnished herewith and not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section or incorporated by reference into any filing under the Securities Act or the Exchange Act. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.